Recently Featured
Laboratory setting for biosimilar development

Fresenius Expands Biosimilars Pipeline with WuXi Biologics Partnership

November 3, 2026
Fresenius is expanding its biosimilars strategy through an exclusive development agreement with WuXi Biologics that could add as many as 37 candidates to its portfolio over the next decade. The agreement provides Fresenius with access to a broader range of biologic drug development programs while allowing the company to retain control over candidate selection, manufacturing…
Buccal drug delivery system concept

Buccal Drug Delivery Market Expected to Grow Significantly

November 3, 2026
The global market for buccal drug delivery systems is projected to maintain strong growth through the end of the decade as pharmaceutical developers pursue alternatives to conventional oral and injectable administration. Increasing interest in faster drug absorption, non-invasive treatment options, and formulations designed to improve patient convenience is creating new opportunities for drug delivery technology…
FDA approval document with a drug

Inovio’s Voceryq Receives FDA Accelerated Approval

November 2, 2026
Inovio has secured accelerated approval from the FDA for Voceryq to minimise the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP). This approval may enhance treatment options for patients suffering from this condition, potentially reducing the need for surgical interventions. Manufacturers and suppliers in the pharmaceutical sector may need to consider the implications…
Awareness campaign for patient safety reporting

MHRA Promotes Yellow Card Reporting for MedSafetyWeek

November 2, 2026
The MHRA is encouraging patients, parents, carers, and healthcare professionals to report suspected side effects through the Yellow Card scheme as part of MedSafetyWeek 2026. This initiative aims to enhance patient safety by increasing awareness and participation in reporting adverse drug reactions. By promoting the Yellow Card scheme, the MHRA seeks to gather more data…

Ongoing Cases